The Objective of This Study is to Evaluate the Perfomance of a Photorefraction Device for Screening Ametropia in Children. Eligible Participants Will Undergo Multiple Refractive Error Measurements, Visual Acuity and Strabismus Assessments During a Single Evaluation Visit.

Evaluation of the Photorefraction Screener Snapsight in Comparison With Cycloplegia Table-top Autorefractor in Ametropia in Pediatric Population Between 3 and 8yo, Multicenter French Study.

The goal of this clinical trial is to evaluate the performance of a photorefraction screener in terms of sensibility, sensitivity and accuracy on children aged 3 to 8 y.o. The main objectives of the study are:

• Evaluate the performances of the device in comparison with the gold standard, i.e. a tabletop refractometer.
• Assess the agreement of the measures obtained with the device with those obtained with the gold standard.

Participants after verification of their eligibility and informed consent, participate to a single evaluation visit during which several objective refraction measurements are performed with the investigational device, a tabletop refractometer and a comparable vision screener with and without cyclopegia. Additionally far vision visual acuity, strabismus assessments and subjective refraction measurement are also performed by investigators.

Inclusion Criteria:

• Aged between 3-8 years when included in the study
• All skin phototypes (I to VI according to the Fitzpatrick classification)
• Wearing glasses or not
• Capacity to give valid consent
• Capacity to follow the protocol to obtain reliable measure
• Under French medical insurance

Exclusion Criteria:

• Under myopia control solution that may have an impact on refractive error (such as: atropine, orthokeratology,..)
• Wearing contact lenses
• Ocular or systemic pathology that may have an impact on vision or may interfere with the study measures (except strabismus)
• Under medication that may have an impact on vision or may interfere with study measurements
• Known contraindication to the active substance or to one of the excipients of eye drops (Mydriaticum 0.5%, Skiacol 0.5%)
• Known risk of angle-closure glaucoma
• Participation to another study that may have an impact on vision or may interfere with the study measures